Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 2/20 | 0.40 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 11/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | DRD1 | P21728 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12035209 | 0.99 | DRD2 (0.41) | DRD2DRD3PDK1ROCK2NPC1 | |
| SCHEMBL740636 | 0.90 | DRD2 (0.36) | DRD2DRD3PDK1ROCK2NPC1 | |
| SCHEMBL4083277 | 0.88 | DRD2 (0.37) | DRD2DRD3PDK1ROCK2NPC1 | |
| Lithium Ion SCHEMBL1503758 | 0.84 | DRD2 (0.39) | DRD2DRD3PDK1ROCK2NPC1 | |
| SCHEMBL1504035 | 0.82 | DRD2 (0.34) | DRD2DRD3PDK1NPC1RAB9A | |
| SCHEMBL15078213 | 0.79 | RAB9A (0.57) | PDK1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12761311 | 0.75 | DRD2 (0.46) | DRD2DRD3PDK1ROCK2NPC1 | |
| Lithium Ion SCHEMBL743158 | 0.74 | DRD2 (0.33) | DRD2DRD3ROCK2DRD1 | |
| SCHEMBL7322498 | 0.74 | DRD3 (0.67) | DRD2DRD3 | |
| SCHEMBL765150 | 0.74 | DRD2 (0.44) | DRD2DRD3PDK1ROCK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1405852-B9 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| CN-1826333-B | Diamine derivatives | DAIICHI SANKYO CO LTD | 2012-12-26 | — | — | CN | disclosed |
| EP-1577301-B1 | Antithrombotic diaminocyclohexane derivatives | DAIICHI SANKYO CO LTD (JP) | 2012-09-12 | — | — | EP | disclosed |
| EP-1405852-B1 | DIAMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2012-08-01 | — | — | EP | disclosed |
| US-20110312990-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-22 | — | — | US | disclosed |
| EP-2343290-A1 | Diamine derivatives as factor X inhibitors | Daiichi Sankyo Company, Limited (JP) | 2011-07-13 | — | — | EP | disclosed |
| US-20110077266-A1 | Diamine Derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-03-31 | — | — | US | disclosed |
| CN-1751025-B | Diamine derivatives | DAIICHI SEIYAKU CO | 2010-05-12 | — | — | CN | disclosed |
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
| US-20100093785-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| CN-1826333-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-08-30 | — | — | CN | disclosed |
| CN-1751025-A | Diamine derivatives | DAIICHI SEIYAKU CO (JP) | 2006-03-22 | — | — | CN | disclosed |
| CN-1745071-A | Novel ethylenediamine derivative | DAIICHI SEIYAKU CO (JP) | 2006-03-08 | — | — | CN | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| EP-1577302-A1 | NOVEL ETHYLENEDIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| EP-1577301-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-09-21 | — | — | EP | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099660-A1 | METHOD FOR TREATING THROMBOSIS OR EMBOLISM AND RELATED DISEASES | F2, PLAT, MPL | DRD2 1524/4885DRD3 1542/4885PDK1 187/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885PDK1 696/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885PDK1 696/4885 |
| US-20100093785-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | DRD2 229/4885DRD3 218/4885PDK1 628/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | DRD2 351/4885DRD3 353/4885PDK1 696/4885 |
| US-20110077266-A1 | Diamine Derivatives | F2, TFPI, F3 | DRD2 1376/4885DRD3 1671/4885PDK1 317/4885 |
| US-20110312990-A1 | Diamine Derivatives | C9, C1S, C1R | DRD2 352/4885DRD3 318/4885PDK1 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.